Altimmune
ALT
21 hedge funds and large institutions have $2.47M invested in Altimmune in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
50% more call options, than puts
Call options by funds: $214K | Put options by funds: $143K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 21 → 21 (0)
2.86% less ownership
Funds ownership: 10.55% → 7.69% (-2.9%)
24% less capital invested
Capital invested by funds: $3.24M → $2.47M (-$774K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$347K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$294K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$134K |
| 4 |
BlackRock
New York
|
+$97.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$759K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$369K |
| 3 |
Renaissance Technologies
New York
|
-$317K |
| 4 |
Squarepoint
New York
|
-$33K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.8K |
ALT Hedge Fund Activity: Q2 2019 in Review
21 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2019, worth a combined $2.47M — down 24% from $3.24M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ALT positions and 5 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $347K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $759K sold.
- 21 institutional investors held Altimmune (ALT) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $2.47M of Altimmune stock for Q2 2019, down 24% quarter-over-quarter.
- 6 funds opened new Altimmune positions in Q2 2019 and 5 closed out, a net change of +1 holder.
- The largest Altimmune buyer in Q2 2019 was Morgan Stanley, an estimated $347K added.
- The largest Altimmune seller in Q2 2019 was Hudson Bay Capital Management, an estimated $759K sold.
Based on aggregated 13F filings for Q2 2019.